Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2025 16:05 ET | Source: Cardiff Oncology, Inc.

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate – – The trial evaluated three doses of...
April 08, 2024 16:05 ET | Source: Cardiff Oncology, Inc.

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor...